Literature DB >> 11413088

Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration.

J Sun1, S O Marx, H J Chen, M Poon, A R Marks, L E Rabbani.   

Abstract

BACKGROUND: Rapamycin is a potent inhibitor of smooth muscle cell (SMC) proliferation and migration. Rapamycin-mediated inhibition of SMC proliferation is associated with upregulation of the cyclin-dependent kinase inhibitor p27(Kip1). Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin. We hypothesized that the antimigratory effect of rapamycin may also be mediated by p27(Kip1). METHODS AND
RESULTS: Rapamycin (1 to 10 nmol/L) inhibited basic fibroblast growth factor-induced migration of wild-type (WT) but not p27(Kip1)(-/-) SMCs in a dose-dependent manner (P<0.05) in a modified Boyden chamber. The effects of rapamycin on aortic SMC explant migration were also studied with WT, p27(+/-), and p27(-/-) mice. Rapamycin 4 mg. kg(-1). d(-1) IP for 5 days inhibited SMC migration by 90% in the WT and p27(Kip1)(+/-) (P<0.05) but not p27(Kip1)(-/-) animals.
CONCLUSIONS: Lack of p27(Kip1) reduces rapamycin-mediated inhibition of SMC migration. These novel findings suggest a role for p27(Kip1) in the signaling pathway(s) that regulates SMC migration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413088     DOI: 10.1161/01.cir.103.24.2967

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

1.  Drug-eluting stents.

Authors:  Xiaodong Ma; Tim Wu; Michael P Robich; Xingwei Wang; Hao Wu; Bryan Buchholz; Stephen McCarthy
Journal:  Int J Clin Exp Med       Date:  2010-07-15

Review 2.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 3.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

Review 4.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 5.  Paclitaxel-eluting stents versus sirolimus-eluting stents in patients with diabetes mellitus undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Hui-Bo Wang; Ping Zeng; Jun Yang; Jian Yang; Xiao-Wen Liu
Journal:  Intern Emerg Med       Date:  2016-09-08       Impact factor: 3.397

6.  Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM.

Authors:  Yann Gouëffic; Susan Potter-Perigo; Christina K Chan; Pamela Y Johnson; Kathleen Braun; Steven P Evanko; Thomas N Wight
Journal:  Atherosclerosis       Date:  2006-12-14       Impact factor: 5.162

7.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

Review 8.  Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors.

Authors:  Nawal Bendris; Bénédicte Lemmers; Jean Marie Blanchard
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors.

Authors:  Daniel J Lightell; T Cooper Woods
Journal:  Ochsner J       Date:  2013

10.  p27Kip1 modulates cell migration through the regulation of RhoA activation.

Authors:  Arnaud Besson; Mark Gurian-West; Anja Schmidt; Alan Hall; James M Roberts
Journal:  Genes Dev       Date:  2004-04-12       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.